Polygenic score

The University of Sydney secured a AU$1.4M grant plus AU$2M from industry and partners with Allelica, Inc. to advance heart disease prevention strategies through Polygenic Risk Score application

Retrieved on:

Monday, June 7, 2021

Circulatory system, Cardiovascular system, Cardiovascular diseases, Aging-associated diseases, Acute pain, Coronary artery disease, Medical emergencies, Cardiovascular disease, Polygenic score, Myocardial infarction, Preventive healthcare, Carotid artery stenosis

The University of Sydney has chosen to partner with Allelica to advance preventive healthcare strategies for coronary artery disease through the clinical application of polygenic risk score in risk assessment.

Key Points:

The University of Sydney has chosen to partner with Allelica to advance preventive healthcare strategies for coronary artery disease through the clinical application of polygenic risk score in risk assessment.
The project is focused on improving heart disease prevention strategies through the application of Allelica's PRS in precision risk assessment.
Existing risk assessments for coronary artery disease focus on cholesterol levels and other risk factors such as smoking status, age and blood pressure.
Consequently, these patients are not prescribed the prevention strategies necessary to reduce the possibility of a heart attack or stroke.

Allelica Raises $1.75 Million in Seed Financing to Advance Polygenic Risk Score (PRS) Analysis into Clinical Practice

Retrieved on:

Friday, March 12, 2021

Health, Infectious diseases, Technology, Genetics, Software, General Health, Pharmaceutical, Branches of biology, PRS, Polygenic score, Precision medicine, Biology, Academic disciplines

The proceeds of the financing will be used to advance clinical integration of Allelicas PRS software into healthcare systems in the US.

Key Points:

The proceeds of the financing will be used to advance clinical integration of Allelicas PRS software into healthcare systems in the US.
By combining PRS with conventional risk factors, Allelica believes precision medicine at scale can be achieved.
Allelica is making great strides towards bringing precision medicine into mainstream clinical practice using PRS.
Allelica is a leading genomic software company specialising in building fast, efficient and scalable solutions to implement clinically accessible polygenic risk scores (PRSs).

Valor Backs Genomics SaaS Platform Allelica

Retrieved on:

Thursday, March 11, 2021

Valor Ventures Fund 2 is pleased to announce its seventh investment, a $1.75 million Series Seed financing of Allelica, Inc. Valor General Partner Gary Peat joins the Allelica board of directors.

Key Points:

Valor Ventures Fund 2 is pleased to announce its seventh investment, a $1.75 million Series Seed financing of Allelica, Inc. Valor General Partner Gary Peat joins the Allelica board of directors.
Says Peat, Allelica brings precision medicine into mainstream clinical practice through a Software-as-a-Service platform for the prediction of complex, genetic diseases using proprietary polygenic risk scores.
With major customers across three continents, Allelica is poised to be the first mass adoption of precision medicine.
Founded in 2015 to create premium venture capital returns with Valors Inclusion Premium strategy, Valor Ventures backs experienced-based founders solving big problems with software at the first professional round.

Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Retrieved on:

Thursday, January 21, 2021

Branches of biology, Biology, Life sciences, Medical genetics, Biotechnology, Medical tests, Animal breeding, Plant breeding, Polygenic score, Molecular diagnostics, Coronavirus disease

MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, Company), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Companys offering to include Germline Testing division.

Key Points:

MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, Company), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Companys offering to include Germline Testing division.
Following further assessment the Company utilized this data to further update and validate the COVID-19 PRS Test.
As previously outlined, Genetic Technologies established the Germline Testing division following the strategic decision to offer hereditary testing for inherited cancer.
Genetic Technologies Limited aims to provide a comprehensive risk assessment service across the full spectrum from sporadic to inherited disease.

New research casts doubt on near reality of 'designer babies'

Retrieved on:

Thursday, November 21, 2019

Branches of biology, Genetics, Statistical genetics, Biology, Classical genetics, Animal breeding, Plant breeding, Polygenic score, Feinstein Institute for Medical Research, Northwell Health, Polygene

However, there has been no research published to indicate the potential success of polygenic embryo selection.

Key Points:

However, there has been no research published to indicate the potential success of polygenic embryo selection.
"Through our research, we can confidently say that trait predictions for embryos based on polygenic scores are not very accurate."
The research team hopes that this work will promote an open and evidence-based discussion of these aspects among the public and policymakers.
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York.